louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02980172: Pain Evaluation and Treatment in the Emergency Department
Official title: Pain Evaluation and Treatment in the Emergency Department
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain, Acute
Emergencies
Keywords: triage
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2016-12-02
Enrollment: 31942
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients admitted during one year at GUH ED.

Brief summary: All patients admitted in Geneva University Hospitals (GUH) emergency department (ED) are triaged using the Swiss Emergency Triage Scale (SETS), a 4-level symptom-based triage scale. At the end of the triage process the triage nurse has to choose an emergency level and a main presenting complaint among a listing of 98 presenting complaints. The SETS recommends a pain evaluation for 44 out of the SETS 98 presenting complaint.

The primary objective of the study is to determine whether pain is correctly evaluated when required by the SETS criteria. The secondary objectives are (1) to evaluate whether an appropriate treatment is delivered when pain is present, and (2) to identify predictors of pain evaluation and treatment.

Detailed description: All patients admitted in Geneva University Hospitals (GUH) emergency department (ED) are triaged using the Swiss Emergency Triage Scale (SETS), a 4-level symptom-based triage scale. At the end of the triage process the triage nurse has to choose an emergency level and a main presenting complaint among a listing of 98 presenting complaints. The SETS recommends a pain evaluation for 44 out of the SETS 98 presenting complaint.

After this evaluation, a protocol standardize administration of analgesia for patients presenting pain.

The primary objective of the study is to determine whether pain is correctly evaluated when required by the SETS criteria for the 44 presenting complaints.

The secondary objectives are (1) to evaluate whether an appropriate treatment is delivered when pain is present, and (2) to identify predictors of pain evaluation and treatment.

Eligibility criteria: Inclusion Criteria:

* adult (\>= 16y) patients admitted at GUH ED during one year
* presenting complaint requiring pain evaluation accordingly to the SETS criteria

Exclusion Criteria:

* \< 16 y
* presenting complaint that does not require a pain evaluation accordingly to the SETS criteria

Primary outcomes:
measure: Proportion of patients with appropriate pain evaluation
timeFrame: Within 24 hours after ED admission
Secondary outcomes:
measure: Proportion of patients with appropriate pain treatment
timeFrame: Within 24 hours after ED admission
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Geneva University Hospitals, ED
Study officials:
affiliation: University Hospital, Geneva
name: Olivier T Rutschmann, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03748472: The Effect of Feeding Length on the Oxygenation Instability Among Premature Infants
Official title: The Effects of Bolus Feeding as Compared to Continuous Gavage Feeding on the Oxygenation Instability During Feeds Among Premature Infants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Premature Infant
Respiratory Disease
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2018-11-20
Enrollment: 24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: SpO2 instability is in the nature of premature infants. Hypoxic episodes occur spontaneously in many of these infants, especially after the first week of life. Different interventions have been shown to influence the incidence of hypoxemic episodes in premature infants. Premature infants are fed via an NG/OG tube. Feeding length might influence the oxygenation instability among premature infants therefore the aim of this study is to evaluate the changes in oxygenation among preterm infants receiving respiratory support when are fed over 30 min vs over 2 hours, as documented by SpO2 histograms.


Eligibility criteria: Inclusion Criteria:

Premature Infants (GA\<37weeks) on non-invasive respiratory support (CPAP, NIPPV, HFNC) Feeding\>100 ml/kg/day

Exclusion Criteria:

Congenital anomalies e.g. gastroschesis, congenital diaphragmatic hernia, cyanotic heart disease.

Instability because of:

Acute lung pathology for example x-ray confirmed pneumonia, air leak Active culture proven sepsis Need for inotropic support for low blood pressure

Primary outcomes:
measure: Oxygenation instability
timeFrame: 9 hours (3 feeds)
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Medical Center
Study officials:
References:
Clinical trial NCT01834872: Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation
Official title: Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Arrhythmias
Lead sponsor: Instituto de Investigación Sanitaria Gregorio Marañón
Sponsor class: OTHER
Collaborators: name: Catheter Robotics, Inc.
First posted: 2013-04-18
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this prospective observational study is to evaluate the performance of Amigo RCS in ablation procedures for most common arrhythmias as compared to a conventional manual approach.


Eligibility criteria: Inclusion Criteria:

* Patients referred to our electrophysiology laboratory to treat any type of arrhythmia with catheter ablation

Exclusion Criteria:

* NA

Primary outcomes:
measure: Ablation Success
timeFrame: 1 year
measure: Safety Endpoint
timeFrame: 1 Year
Secondary outcomes:
measure: Acute Ablation Success
timeFrame: During Procedure
measure: Acute Safety Endpoint
timeFrame: During Procedure
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Marañón
Study officials:
References:
citation: Datino T, Arenal A, Pelliza M, Hernandez-Hernandez J, Atienza F, Gonzalez-Torrecilla E, Avila P, Bravo L, Fernandez-Aviles F. Comparison of the safety and feasibility of arrhythmia ablation using the Amigo Robotic Remote Catheter System versus manual ablation. Am J Cardiol. 2014 Mar 1;113(5):827-31. doi: 10.1016/j.amjcard.2013.11.030. Epub 2013 Dec 12.
Clinical trial NCT02432872: Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
Official title: A Multicenter，Open-label，Radonmized Study on the Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years Old
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Myeloid Leukemia
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2015-05-04
Enrollment: 300
Sex: ALL
Minimum age (years): 55
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the escalation dosage of Daunorubicin and cytarabine is effective and safety in the treatment of older adult Chinese acute myeloid leukemia（AML） patients aged 55 to 65 years.

Detailed description: the DA 3+7 regimen is the standard therapy in the AML treatment.Escalated dosage of daunorubicin in induction therapy is reported effective and result in a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects in elderly AML patients between 60 to 65 years.Higher Overall survival rate and Event-free survival rate was obtained in escalated group compared with conventional dose. We are wondering if Chinese older AML patients can benefit from this escalated induction regimen.

High dose cytarabine in AML consolidation is reported improving the survival of elderly AML patients than the conventional dose，but it is not determined in Chinese older adult AML patients.

Eligibility criteria: Inclusion Criteria:

* primary AML（except APL patients）;
* ECOG PS:0-2

Exclusion Criteria:

* AML patient who has already received induction treatment, no matter what the outcome is;
* Treatment-related AML;
* Active cancer patients who's condition need to be treated;
* The one with serious infectious diseases（eg.uncontrolled tuberculosis or invasive pulmonary aspergillosis）
* Active heart disease.

Primary outcomes:
measure: overall survival
timeFrame: 3 years
Secondary outcomes:
measure: complete remission rate
timeFrame: 2 months
measure: relapse free survival
timeFrame: 3 years
measure: complete remission rate in different risk group
timeFrame: 2 month
measure: treatment-related mortality
timeFrame: 2 months
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Treatment and Diagnosis Center of Leukemia
state: Tianjin
Study officials:
affiliation: ChineseAMS
name: Jianxiang Wang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02289872: Pediatric Intubation
Official title: Comparison of the TruView PCD Video Laryngoscope and Macintosh Laryngoscope for Pediatric Tracheal Intubation by Novice Paramedics: A Randomized Crossover Simulation Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intubation
Cardiac Arrest
Lead sponsor: International Institute of Rescue Research and Education
Sponsor class: OTHER
First posted: 2014-11-13
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of the study was to compare time and success rates of TruView PCD video laryngoscope and Macintosh laryngoscope for the pediatric emergency intubation with three airway scenarios in a standardized manikin model.


Eligibility criteria: Inclusion Criteria:

* give voluntary consent to participate in the study
* inexperienced in pediatric intubation paramedics

Exclusion Criteria:

* not meet the above criteria
* participants who had performed intubation in pediatric humans prior the trial or had previously TruView experience

Primary outcomes:
measure: Time to intubation
timeFrame: 1 day
Secondary outcomes:
measure: Success of intubation
timeFrame: 1 day
measure: Cormack-Lehan scale
timeFrame: 1 day
measure: Dental compression
timeFrame: 1day
measure: Ease of intubation (VAS)
timeFrame: 1 day
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: International Institute of Rescue Research and Education
state: Masovie
Study officials:
References:
citation: Szarpak L, Czyzewski L, Kurowski A, Truszewski Z. Comparison of the TruView PCD video laryngoscope and macintosh laryngoscope for pediatric tracheal intubation by novice paramedics: a randomized crossover simulation trial. Eur J Pediatr. 2015 Oct;174(10):1325-32. doi: 10.1007/s00431-015-2538-0. Epub 2015 Apr 18.
Clinical trial NCT02140372: Anti-platelet Effects of Colchicine in Healthy Volunteers
Official title: Anti-platelet Effects of Colchicine in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy
Keywords: colchicine
platelet activity
neutrophil
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2014-05-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a pilot study. Volunteers will be given 1.8 mg (1.2 mg followed by 0.6 mg one hour later), 1.2 mg, or 0.6 mg of colchicine. Blood will be collected prior to drug administration, 2 hours after colchicine administration, and 24 hours after colchicine administration via the antecubital vein and evaluated for markers of platelet activity and inflammation.


Eligibility criteria: Inclusion Criteria:

* Subjects must be more than 18 years of age

Exclusion Criteria:

1) history of cardiovascular disease, including myocardial infarction, history of percutaneous coronary angioplasty or stent, peripheral vascular disease or stroke; 2) history of myelodysplasia; 3) medications known to affect platelet function, including non-steroidal anti-inflammatory drugs, antihistamines, and selective serotonin reuptake inhibitors, during the 5 days prior to participation; 4) medications known to interact with colchicine; 5) history of intolerance to colchicine; 6) acute or chronic symptoms of diarrhea, nausea, or vomiting within 1 month prior to enrollment; 7) known anemia or hemoglobin \<10mg/dL; 8) platelet count \<100,000 or \> 450,000; 9) creatinine clearance \<30cc/minute; 10) any known hemorrhagic diathesis; 11) pregnant; 12) Unable to consent; or 13) Participating in a competing study.

Primary outcomes:
measure: Monocyte Platelet Aggregate: Baseline
timeFrame: Baseline
measure: Monocyte Platelet Aggregate: 2 Hours
timeFrame: 2 Hours
Secondary outcomes:
measure: Light Transmission Aggregometry: Baseline
timeFrame: Baseline
measure: Light Transmission Aggregometry: 2 Hours
timeFrame: 2 hours
measure: Light Transmission Aggregometry: Baseline
timeFrame: baseline
measure: Light Transmission Aggregometry: 2 Hours
timeFrame: 2 hours
measure: Platelet Adhesion: Baseline
timeFrame: Baseline
measure: Platelet Adhesion: 2 Hours
timeFrame: 2 hours
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU SOM
name: Binita Shah, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01698372: Negative Pressure Dressing After Saphenous Vein Harvest
Official title: Negative Pressure Dressing to Decrease the Incidence of Leg Wound Complications After CABG
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Coronary Artery Disease
Complication of Coronary Artery Bypass Graft
Wound Complication
Keywords: Cardiac surgery.
Wound healing.
Leg wound infection.
Wound care.
Lead sponsor: University of Calgary
Sponsor class: OTHER
Collaborators: name: KCI USA, Inc
First posted: 2012-10-03
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study will test the effectiveness of negative pressure wound therapy (using the VAC Prevena device, KCI Canada Inc.) applied to the saphenous vein harvest site after Coronary Artery Bypass Grafting (CABG). When initiated immediately after surgery, this intervention may decrease the incidence of wound infection and non-infectious wound complications. It may decrease wound discomfort and improve mobility and functional recovery of the leg.


Eligibility criteria: Inclusion Criteria:

* Patients presenting for elective or semi-elective isolated first-time CABG surgery with harvesting of the greater saphenous vein.
* Must be 18 years or older.
* Must live with one hour driving distance from Calgary.
* Must provide written consent.

Exclusion Criteria:

* Previous CABG surgery or previous lower leg surgical intervention.
* In emergent need for surgery.
* Have severe peripheral vascular disease.
* Do not speak and read the English language.
* Have dialysis-dependent renal failure.
* Require chronic steroids.
* Unable to return to clinic for follow-up due to functional or cognitive impairment.

Primary outcomes:
measure: Change from baseline ASEPSIS score of wound healing at 6 weeks.
timeFrame: Baseline and 6 weeks
Secondary outcomes:
measure: Total score of pain level.
timeFrame: Baseline and 6 weeks
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Libin Cardiovascular Institute, Foothills Medical Centre
state: Alberta
Study officials:
affiliation: University of Calgary
name: Paul Fedak, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lee AJ, Sheppard CE, Kent WD, Mewhort H, Sikdar KC, Fedak PW. Safety and efficacy of prophylactic negative pressure wound therapy following open saphenous vein harvest in cardiac surgery: a feasibility study. Interact Cardiovasc Thorac Surg. 2017 Mar 1;24(3):324-328. doi: 10.1093/icvts/ivw400.
Clinical trial NCT03241472: Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole
Official title: Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Infertility
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-08-07
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Infertility is defined as a couple's inability to become pregnant after one year of unprotected intercourse in women 35 years old and younger, and for six months in women over age 35 years. In any given year, about 15 percent of couples in North America and Europe who are trying to conceive are infertile


Eligibility criteria: Inclusion Criteria:

* All primary and secondary. Infertility due to anovulation

Exclusion Criteria:

* Male factor infertility, tubal factor.
* Endocrineopathy
* Hypothyrodism
* Morbid obesity
* Under weight
* Patient with previous surgery including drilling of ovary, Clomiphene Citrate resistant to ovulation.

Primary outcomes:
measure: rate of ovulation
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04952272: Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Official title: Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Lung Cancer
Hepatocellular Carcinoma
Solid Tumor
Lead sponsor: Second Affiliated Hospital of Guangzhou Medical University
Sponsor class: OTHER
Collaborators: name: Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
First posted: 2021-07-07
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.

Detailed description: 1. Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens
2. Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40
3. Assessing side effects and therapeutic efficacy after the combined treatments

Eligibility criteria: Inclusion Criteria:

* Solid advanced malignant tumors
* Age between18 and 80 years
* Life expectancy is greater than three months

Exclusion Criteria:

* Benign tumor
* Life expectancy is less than three months
* Serious medical comorbidity
* Others

Primary outcomes:
measure: Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors
timeFrame: up to 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: The Second Affiliated Hospital of Guangzhou Medical University
state: Guangdong
Study officials:
affiliation: Second Affiliated Hospital of Guangzhou Medical University
name: Zhenfeng Zhang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05469672: The Effect of Laser Therapy in the Management of Adhesive Capsulitis: a Randomized Clinical Trial
Official title: The Effect of Low-level Laser Versus High-intensity Laser Therapy in the Management of Adhesive Capsulitis: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain Disorder
Low Level Laser Therapy
Keywords: Adhesive capsulitis Pain
High-intensity laser therapy
Low-level laser therapy
Pain
Lead sponsor: Necmettin Erbakan University
Sponsor class: OTHER
First posted: 2022-07-22
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, it was aimed to compare the effects of low-level laser therapy (LLLT) and high-intensity laser therapy (HILT) on shoulder joint range of motion, level of pain and functional status in patients with adhesive capsulitis

Detailed description: This study will be designed as a randomized, prospective, single-blind clinical trial with a 3-week follow-up. A total of 50 patients who applied to our hospital with the complaint of shoulder pain will be evaluated for inclusion in the study. Patients will be randomized into two groups as high-intensity laser (HILT) + stretching exercise group and low-level laser (LLLT) + stretching exercise group.

Eligibility criteria: Inclusion Criteria:

1. patients aged between 25-65 years
2. patients clinically diagnosed with adhesive capsulitis, characterized by limitation of passive external rotation of the affected shoulder to less than 50% of the contralateral shoulder and normal radiographic finding of the affected shoulder
3. patients with severe pain and shoulder limitation for at least 3 months
4. patients who are literate and able to understand verbal instructions in our language.

Exclusion Criteria:

1. Calcific tendinopathy, glenohumeral osteoarthritis, fracture, shoulder surgery, shoulder trauma, history of malignancy and infection, history of inflammatory rheumatic diseases
2. History of bilateral simultaneous adhesive capsulitis
3. Recent history of lung, breast, or bypass surgery/radiotherapy
4. History of corticosteroid injection to the same shoulder in the last 1 year
5. History of cervical radiculopathy/brachial plexus lesion
6. Neuromuscular disease history
7. History of physical therapy program for the same shoulder in the last 6 months.

Primary outcomes:
measure: Visual Analog Scale (VAS) is used to measure and monitor the intensity of pain. Change from baseline in pain on the VAS at week 3
timeFrame: Baseline-Week 3
Secondary outcomes:
measure: Shoulder Pain and Disability Index
timeFrame: Baseline and week 3
measure: Measuring the range of motion at shoulder joint
timeFrame: Baseline and week 3
Other outcomes:
Locations:
Study officials:
affiliation: Meram Medical School, Necmettin Erbakan University, Konya, Turkey
name: BANU ORDAHAN
role: PRINCIPAL_INVESTIGATOR
References: